cytisine
DrugListed as a natural health product in Canada, cytisine is utilized to aid in smoking cessation
NCT Number: NCT05102123
PREVENT is a multicentre, 2x2 factorial, randomized clinical trial that aims to determine the effect of cytisine versus placebo, as well as the effect of video messaging to support smoking cessation versus standard of care in perioperative patients. This trial aims to investigate the effects of cytisine and text messaging on 6-month continuous abstinence rates. PREVENT will also assess secondary outcomes at 30 days, 56 days and 6 months post-randomization: 7-day point prevalence abstinence, urge to smoke, time to first lapse, time to relapse, number of cigarettes smoking if still smoking, pulmonary complications, vascular complications, wound and infectious complications, stroke, time in hospital and acute hospital care.
This study is active but is not currently recruiting participants.
18 year and older
All sexes
Interventional
Phase 3
Hamilton General Hospital, Hamilton, Ontario, Canada
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Listed as a natural health product in Canada, cytisine is utilized to aid in smoking cessation
Supportive messaging utilizing a video messaging platform to encourage patients to abstain from smoking throughout the treatment period.
Time frame: 6 months
complete abstinence (smoking not more than 5 cigarettes) beginning on day 5 post randomization and lasting until the assessment at 6 months post-randomization with biochemical verification for those who report abstinence, using exhaled breath carbon monoxide (cut-off <10 parts per million [ppm]) measured with a carbon monoxide (CO) monitor
Time frame: 30 days
Self-report of not smoking cigarettes [not even a puff] in the 7 days before the 30-day follow-up
Time frame: 56-days
Self-report of not smoking cigarettes [not even a puff] in the 7 days before the 56-day follow-up
Time frame: 6-months
Self-report of not smoking cigarettes [not even a puff] in the 7 days before the 6-month follow-up
Time frame: baseline and 6-months
urge to smoke using the Mood and Physical Symptoms Scale [MPSS] at baseline and 6 months; a higher score indicates a stronger urge to smoke; To assess the effect of abstinence calculate the change from baseline (just prior to stopping smoking) to the post-abstinence follow-up point for items 1 to 7 and 10 to 12, and take the raw scores for items 8 and 9
Time frame: 30 days, 56 days and 6 months
Number of cigarettes smoked daily if still smoking
Time frame: 6 months
Time to first cigarette smoked after the initial quit, even a single puff
Time frame: 6 months
Time to return to regular smoking for three or more concurrent days after a period of abstinence.
Time frame: 6-months
Complete abstinence (smoking not more than 5 cigarettes) beginning on the quit date and lasting until the assessment at 6 months post-randomization with biochemical verification for those who report abstinence, using exhaled breath carbon monoxide (cut-off <10 ppm) measured with a carbon monoxide (CO) monitor.
*Cigarettes smoked within 5 days of randomization will be discounted.
Time frame: 6 months
Seroma- wound drainage or repeated dressings required; Wound dehiscence or delayed wound healing
Time frame: 6 months
Infection - defined as a pathologic process caused by the invasion of normally sterile tissue, fluid, or body cavity by pathogenic or potentially pathogenic organisms.
Surgical site infection- An infection that occurs within 30 days after surgery and involves the skin, subcutaneous tissue of the incision (superficial incisional), or the deep soft tissue (e.g., fascia, muscle) of the incision (deep incisional).
Sepsis- Based on the Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). Sepsis requires a quick Sequential Organ Failure Assessment (qSOFA) Score ≥2 points due to infection. The qSOFA includes the following items and scoring system: 1. altered mental status (1 point); 2. systolic blood pressure ≤100 mm Hg (1 point); and 3. respiratory rate ≥22 breaths per minute (1 point).
Time frame: 6 months
Pneumonia - defined as an acute infection of the pulmonary parenchyma that is associated with at least one sign or symptom of lower respiratory acute infection (e.g., cough, pleuritic chest pain) or acute systemic illness (e.g., fever, chills, confusion, hypoxemia); accompanied by the presence of an acute infiltrate/consolidation on a chest radiograph or auscultatory findings consistent with pneumonia (such as crackles and/or localized rales) for which there is no other explanation.
Respiratory insufficiency requiring ventilatory support - Patient intubated or put on bilevel positive airway pressure (BiPAP).
Time frame: 6 months
according to the 4th universal definition
Time frame: 6 months
The diagnosis of PE requires any one of the following:
The diagnosis of proximal DVT (leg or arm) requires:
Time frame: 6 months
Stroke is defined as either: 1. a new focal neurological deficit thought to be vascular in origin with signs or symptoms lasting ≥24 hours or leading to death; or 2. a new focal neurological deficit thought to be vascular in origin with signs or symptoms lasting <24 hours with positive neuroimaging consistent with a stroke.
Time frame: 6 months
Nonfatal cardiac arrest is defined as successful resuscitation from either documented or presumed ventricular fibrillation, sustained ventricular tachycardia, asystole, or pulseless electrical activity requiring cardiopulmonary resuscitation, pharmacological therapy, or cardiac defibrillation.
Time frame: 6 months
The definition of death is all cause mortality.
Time frame: time of hospital admission to time of discharge for surgical stay
Defined as time of hospital admission to time of discharge from hospital after index surgery.
Time frame: after hospital discharge for the study surgery to 6-month follow-up
Acute-hospital care is a composite outcome of hospital re-admission (patient admission to an acute-care hospital) and emergency department visit (patient visit to an emergency department, which includes urgent-care centre visit).
Time frame: 6-months
Data on hospital re-admission, healthcare utilization, and costs of health service utilization will be obtained from the Institute for Clinical Evaluative Sciences data repository. Administrative databases used to describe the health service utilization include: 1. Registered Persons Database - demographics and vital statistics of all legal residents of Ontario; 2. Discharge Abstract Database - records of inpatient hospitalizations from the Canadian Institute for Health Information (CIHI); 3. Ontario Health Insurance Plan Database - physician billing claims, and the National Ambulatory Care Reporting System - information on emergency department visits from CIHI.
Time frame: baseline and 6-months
HRQoL will be measured with the EQ-5D-5L instrument (https://euroqol.org/eq-5d-instruments/sample-demo) due to its increased sensitivity and validation in several countries including Canada. The EQ-5D-5L is also recommended in Canada to calculate the Quality Adjusted Life Years (QALYs) when conducting cost-effectiveness analyses.
Population Health Research Institute
Other
Acronym: PREVENT
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07145866
Behavior, Behavior, Addictive
Boston, Massachusetts, United States
View Trial DetailsNCT07301151
Behavior, Behavior, Addictive
Minneapolis, Minnesota, United States
View Trial DetailsNCT07593742
Behavior, Behavior, Addictive
View Trial DetailsNCT07553962
Behavior, Behavior, Addictive
Denver, Colorado, United States
View Trial Details